COMPARATIVE MRD ASSESSMENT AND IMMUNE PROFILING IN R/R CLL TREATED WITH VENETOCLAX-RITUXIMAB: INSIGHTS FROM "DEDALUS" (SIE 2026) - Oct 6, 2026 - Abstract #SP023; "While MFC remains a standardized and accessible tool, NGS provides enhanced sensitivity that better aligns with long-term outcomes. These data support further explo- ration of digital PCR for IgH monitoring and a deeper inter- rogation of Venetoclax-mediated immunomodulation."
Chronic Lymphocytic Leukemia • Hematological Malignancies • Immunology • Leukemia • CD4 • CD8
|
|
M. D'Amato1; C. Baratè2; C. Bono1; F. Guerrini1; G. Tancredi1; E. Benedetti1; S. Galimberti1
|